FDA.reportPublic FDA data

ubrogepant 50 MG Oral Tablet [Ubrelvy]

RxCUI
2268231
RxNorm name
ubrogepant 50 MG Oral Tablet [Ubrelvy]
Display name
ubrogepant 50 MG Oral Tablet [Ubrelvy]
Full name
ubrogepant 50 MG Oral Tablet [Ubrelvy]
Term type
SBD
Status
DailyMed mapping
Updated
2026-06-04 23:39:29

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
fd9f9458-fd96-4688-be3f-f77b3d1af6abubrelvy 50 MG Oral Tablet [PSN] · ubrogepant 50 MG Oral Tablet [Ubrelvy] [SBD] · Ubrelvy 50 MG Oral Tablet [SY]327These highlights do not include all the information needed to use UBRELVY safely and effectively. See full prescribing information for UBRELVY. UBRELVY ® (ubrogepant) tablets, for oral use Initial U.S. Approval: 201920250605